Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial to evaluate the efficacy and safety of Dapirolizumab Pegol in participants with moderately to severely active systemic lupus erythemato…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Dapirolizumab Pegol (dapirolizumab pegol)

Snippet

Sponsor: UCB Biopharma SRL | Conditions: Systemic Lupus Erythematosus | Phase 3 | Status: RECRUITING